Quick Answer
CollPlant Biotechnologies Ltd reported Total Revenue of $2.37 million for fiscal year 2025.
CollPlant Biotechnologies Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.37M +360.4% |
$515.0K -95.3% |
$10.96M +3565.2% |
$299.0K -98.1% |
$15.64M +154.9% |
$6.14M +164.8% |
| Net Income | -$11.49M +30.8% |
-$16.61M -136.6% |
-$7.02M +58.5% |
-$16.93M -7241.4% |
$237.0K +104.1% |
-$5.77M +48.3% |
| Diluted EPS | -$0.94 +35.2% |
-$1.45 -133.9% |
-$0.62 +59.5% |
-$1.53 -7750.0% |
$0.02 +102.4% |
-$0.84 +62.3% |
| Total Assets | $10.79M -42.4% |
$18.71M -45.2% |
$34.13M -9.6% |
$37.77M -26.3% |
$51.22M +372.5% |
$10.84M +0.8% |
| Cash and Equivalents | $5.59M -53.1% |
$11.91M -55.4% |
$26.67M -10.0% |
$29.65M +125.5% |
$13.15M +294.5% |
$3.33M -12.1% |
| Stockholders Equity | $6.08M -54.8% |
$13.46M -52.5% |
$28.34M -12.2% |
$32.28M -28.5% |
$45.12M +907.8% |
$4.48M +9.5% |
| R&D Expense | $8.19M -22.1% |
$10.52M +0.3% |
$10.48M +2.2% |
$10.26M +34.4% |
$7.63M +87.7% |
$4.07M -7.9% |
| Operating Income | -$11.48M +33.4% |
-$17.25M -129.6% |
-$7.51M +56.1% |
-$17.10M -26403.1% |
$65.0K +101.2% |
-$5.60M +26.6% |
| Gross Profit | $1.54M +238.4% |
-$1.11M -112.4% |
$8.97M +8979.2% |
-$101.0K -100.7% |
$13.64M +335.0% |
$3.13M +614.1% |
| Shares Outstanding | 12.80M +11.8% |
11.45M +0.0% |
11.45M +2.4% |
11.19M +3.8% |
10.77M +54.7% |
6.96M +22.8% |
- CollPlant Biotechnologies Ltd reported Total Revenue of $2.37 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +360.4% in Total Revenue compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Net Income of -$11.49 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +30.8% in Net Income compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Diluted EPS of $0.94 per share (loss) for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +35.2% in Diluted EPS compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Total Assets of $10.79 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed a decrease of -42.4% in Total Assets compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Cash and Equivalents of $5.59 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed a decrease of -53.1% in Cash and Equivalents compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Stockholders Equity of $6.08 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed a decrease of -54.8% in Stockholders Equity compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported R&D Expense of $8.19 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed a decrease of -22.1% in R&D Expense compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Operating Income of -$11.48 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +33.4% in Operating Income compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Gross Profit of $1.54 million for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +238.4% in Gross Profit compared to the prior fiscal year.
- CollPlant Biotechnologies Ltd reported Shares Outstanding of 12.80 million shares for fiscal year 2025.
- CollPlant Biotechnologies Ltd showed an increase of +11.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: